This educational series explores the evolving role of radiation therapy in managing nonmalignant conditions, addressing current challenges, emerging evidence, and specialized applications in clinical practice.
This activity is a case-based discussion on the role of radiation therapy in the treatment of cutaneous squamous cell carcinoma. We have three academic physicians representing three different geographic locations within the United States, from the east coast, west coast and sun belt region.
With technological advances re-irradiation has rapidly become common and an important part of cancer management to new or recurrent tumors, yet is clinically challenging given risks of serious toxicity from cumulative doses.
Radiopharmaceutical Therapy (RPT) is an emerging modality with significant potential to impact future oncological management across many disease settings.
Theranostics, a treatment paradigm pairing diagnostic molecular imaging with radiopharmaceutical therapy (RPT), is resurgent, mainly driven by the FDA approvals of 177Lu-dotatate for neuroendocrine tumors and 177Lu-PSMA-617 for prostate cancer.
Radiation dosimetry plays a critical role in the development and application of radiotherapeutic pharmaceuticals, ensuring both efficacy and safety in treatment.
Patient reported outcomes (PROs) are a key component of evaluating cancer therapy. For clinical trialists, the proper design, implementation and evaluation of patient reported outcomes is critical for designing studies that will impact and inform daily practice.
Facebook
X
LinkedIn
Forward
